Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials

Ann Oncol. 2022 Feb;33(2):119-122. doi: 10.1016/j.annonc.2021.11.008. Epub 2021 Nov 26.

Authors

I Attili¹, A Passaro², F de Marinis²

Affiliations

¹ Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy. Electronic address: ilaria.attili@ieo.it.
² Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.

PMID: 34839015
DOI: 10.1016/j.annonc.2021.11.008

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Immune Checkpoint Inhibitors* / pharmacology
Immune Checkpoint Inhibitors* / therapeutic use
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics

Substances

Immune Checkpoint Inhibitors